Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Dr Agarwal'S Eye Hospital's Debt-to-EBITDA or its related term are showing as below:
BOM:526783'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0.71 Med: 2.17 Max: 3.29
Current: 2.06
During the past 13 years, the highest Debt-to-EBITDA Ratio of Dr Agarwal'S Eye Hospital was 3.29. The lowest was 0.71. And the median was 2.17.
BOM:526783's Debt-to-EBITDA is ranked better than 52.5% of 480
companies
in the Healthcare Providers & Services industry
Industry Median: 2.185
vs BOM:526783: 2.06
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Dr Agarwal'S Eye Hospital Debt-to-EBITDA Related Terms
Dr Agarwal'S Eye Hospital Debt-to-EBITDA Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BOM:526783 vs HCA, THC, DVA: Debt-to-EBITDA Comparison
For the Medical Care Facilities subindustry, Dr Agarwal'S Eye Hospital's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Dr Agarwal'S Eye Hospital Debt-to-EBITDA vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Dr Agarwal'S Eye Hospital's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Dr Agarwal'S Eye Hospital's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Jun. 2026) EBITDA data.
Dr Agarwal'S Eye Hospital (BOM:526783) has a Debt-to-EBITDA of 0.00 as of Jun. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Dr Agarwal'S Eye Hospital. Over the past decade, Dr Agarwal'S Eye Hospital's Debt-to-EBITDA has ranged from 0.71 to 3.29. According to the industry distribution chart, Dr Agarwal'S Eye Hospital ranks #228 out of 480 companies in the Healthcare Providers & Services industry, placing it in the top 47.5%.
Is Dr Agarwal'S Eye Hospital's Debt-to-EBITDA too high?
Dr Agarwal'S Eye Hospital's current Debt-to-EBITDA is 0.00. Over the past 10 years, this metric has ranged from a low of 0.71 to a high of 3.29. Based on the distribution chart, Dr Agarwal'S Eye Hospital ranks #228 out of 480 companies in the Healthcare Providers & Services industry, which is above the industry midpoint. Overall, Dr Agarwal'S Eye Hospital has a GF Score™ of 94/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Dr Agarwal'S Eye Hospital's Debt-to-EBITDA compare to HCA and THC?
According to the Healthcare Providers & Services industry distribution chart, Dr Agarwal'S Eye Hospital ranks #228 out of 480 companies for Debt-to-EBITDA. This puts Dr Agarwal'S Eye Hospital in the upper half of its industry. The industry median Debt-to-EBITDA is 2.19. Historically, Dr Agarwal'S Eye Hospital's own Debt-to-EBITDA has ranged from 0.71 to 3.29 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Healthcare Providers & Services company?
The median Debt-to-EBITDA among Healthcare Providers & Services companies is 2.19, based on 480 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Dr Agarwal'S Eye Hospital. For the Healthcare Providers & Services industry, the median Debt-to-EBITDA is 2.19 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Dr Agarwal'S Eye Hospital's current Debt-to-EBITDA is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Dr Agarwal'S Eye Hospital stock overvalued right now?
Based on GuruFocus' analysis, Dr Agarwal'S Eye Hospital (BOM:526783) is currently considered Fairly Valued. The stock's GF Value™ is ₹5,511.79, compared to a current price of ₹5,373.85 — trading 2.5% below its estimated fair value. The current Debt-to-EBITDA is 0.00. Dr Agarwal'S Eye Hospital's overall GF Score™ is 94/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Dr Agarwal'S Eye Hospital (BOM:526783), the current Debt-to-EBITDA is 0.00 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Dr Agarwal'S Eye Hospital (BOM:526783) Overvalued in 2026?
Based on GuruFocus' analysis, Dr Agarwal'S Eye Hospital stock appears to be undervalued.
The current stock price of ₹5,373.85 is trading 2.5% below its estimated GF Value™ of ₹5,511.79.
GuruFocus considers Dr Agarwal'S Eye Hospital to be Fairly Valued.
Key valuation signals for BOM:526783:
Debt-to-EBITDA: 0.00
GF Value™: ₹5,511.79 vs. price of ₹5,373.85 (2.5% below fair value)
No single metric tells the full story. See the BOM:526783 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Dr Agarwal'S Eye Hospital Ltd is a provider of eye care and related services. The company is predominantly engaged in running, owning and managing eye care hospitals, opticals, pharmacies, and related services. It operates across various locations in India and provides solutions like Refractive Surgery, Lasik Surgery, Oculoplasty, Laser Cataract Surgery, and SMILE Eye Surgery among others.
94GF Score
Get the complete analysis for BOM:526783
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:526783 has been successfully added to your 
